Research summary
Berberine and Fatty Liver
Quick answer
A 2024 meta-analysis of 10 randomized controlled trials (811 adults) found that berberine, used as an adjunct in non-alcoholic fatty liver disease, was associated with significant reductions in the liver enzymes ALT, AST and GGT, alongside improvements in lipid and insulin-resistance markers, and reported only mild gastrointestinal adverse events. A 2025 systematic review reached broadly similar conclusions but pooled only a small number of clinical trials together with preclinical data, and both reviews emphasize that doses were not standardized and that larger, well-designed trials are still needed.[1], [2]
Limitations
Findings come from meta-analyses of a small number of mostly small randomized controlled trials with non-standardized berberine doses, varying durations and significant heterogeneity in some outcomes, and the 2025 review combined limited clinical data with preclinical animal studies. Outcomes were biochemical markers such as liver enzymes rather than long-term clinical endpoints, so the durability and real-world relevance of these effects remain uncertain.[1], [2]
What does the evidence support?
Read each finding with its qualification. These are source-supported statements, not a ranking of products or personal treatment advice.
| Finding and qualification | References |
|---|---|
| In a meta-analysis of randomized controlled trials in adults with non-alcoholic fatty liver disease, oral berberine taken as an adjunct was associated with significant reductions in liver enzymes (ALT, AST and GGT). Based on a 2024 meta-analysis of 10 randomized controlled trials (811 patients); berberine doses varied across the included trials and it was used as an adjunct rather than a stand-alone therapy. The studied dose was oral berberine (dose not standardized across included trials). | [1], [2] |
| Across the randomized controlled trials pooled in a 2024 meta-analysis, berberine was reported to have a favorable safety profile, with only mild gastrointestinal adverse events. Based on adverse events reported in a 2024 meta-analysis of 10 randomized controlled trials (811 patients); doses varied across trials and long-term safety was not established. The studied dose was oral berberine (dose not standardized across included trials). | [1] |
| Current evidence for berberine in non-alcoholic fatty liver disease comes from a limited number of small randomized controlled trials with non-standardized doses, and authors call for further well-designed trials before firm conclusions can be drawn. Reflects the limitations noted by the 2024 meta-analysis (10 trials) and a 2025 systematic review that pooled only 4 clinical trials alongside preclinical animal data. | [1], [2] |
What the trials measured
Non-alcoholic fatty liver disease (NAFLD) is characterized by excess fat in the liver and is commonly tracked using blood markers of liver function. A 2024 meta-analysis that pooled 10 randomized controlled trials, covering 811 patients, examined whether berberine taken as an adjunct affected these markers. The primary outcomes included liver enzymes such as alanine transaminase (ALT), aspartate transaminase (AST) and glutamyl transpeptidase (GGT), as well as lipid indices, insulin resistance and body mass index.[1]
In that pooled analysis, berberine was associated with statistically significant reductions in the liver enzymes ALT, AST and GGT compared with control. The authors framed berberine as a potential adjunct therapy rather than a stand-alone treatment, and the size of the effect varied across the included trials.[1]
Tolerability reported in the trials
Across the randomized controlled trials gathered in the 2024 meta-analysis, the authors reported a favorable safety profile for berberine, noting only mild gastrointestinal adverse events among participants. This reflects short-to-medium-term tolerability within the studied trials and does not establish long-term safety.[1]
How strong is the evidence
The supporting evidence remains limited in scope. The 2024 meta-analysis drew on 10 generally small trials, and a 2025 systematic review and meta-analysis was able to pool only four clinical trials alongside 18 preclinical animal studies. Both reviews note that berberine doses were not standardized across studies and explicitly call for further rigorous, well-designed trials before firm conclusions can be drawn.[1], [2]
Taken together, the current human evidence points toward improvements in liver enzymes and a generally mild adverse-event profile, but the modest number of trials, non-standardized dosing and reliance on biochemical markers mean these findings are best read as promising rather than definitive. This article is informational and is not medical advice.[1], [2]
Are lower liver enzymes evidence that fatty liver is reversed?
ALT, AST, and GGT were measured markers in the pooled trials; they are not the same endpoint as reversal of fibrosis or prevention of liver-related illness. The 2024 synthesis included 10 trials and 811 participants, with berberine used as an adjunct and doses that were not standardized. Its favorable enzyme results should not be rewritten as proof of a cure.[1], [2]
Likewise, mild gastrointestinal events reported in these trials do not establish safety for indefinite use or in every stage of liver disease. The limited study base and inconsistent protocols are reasons to keep established care and clinical follow-up central when considering the research.[1], [2]
References
- The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review.. Journal of translational medicine. 2024. Systematic review and meta-analysis View source →
- Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research.. Frontiers in pharmacology. 2025. Systematic review View source →
Continue from here
Use the main FAQ hub to place this research summary in context alongside dosing, forms, safety, and product-selection questions.